Studieoverzicht

 
 
 
  2022-01 DIRECT-2       Open       Neoadjuvant       HER2- HR+       Both pre- and postmenopausal  
  2021-03 EMBER-3       Open       Advanced/metastatic       HER2- HR+       Both pre- and postmenopausal  
  2021-01 SEQUEL-Breast       Open       Advanced/metastatic       HER2- HR+       Both pre- and postmenopausal  
  2019-01 TIBET       Open       Advanced/metastatic       HER2- HR+       Both pre- and postmenopausal